Differential mechanisms of acquired resistance to insulin-like growth factor-I receptor antibody therapy or to a small-molecule inhibitor, BMS-754807, in a human rhabdomyosarcoma model

Cancer Research

Volumn 70, Issue 18, 2010, Pages 7221-7231

  Huang, Fei ^a   Hurlburt, Warren ^a   Greer, Ann ^a   Reeves, Karen A ^a   Hillerman, Stephen ^a   Chang, Han ^a   Fargnoli, Joseph ^a   Finckenstein, Friedrich Graf ^a   Gottardis, Marco M ^a   Carboni, Joan M ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BMS 754807; MAB 391; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; SMALL INTERFERING RNA; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG; 1 [4 [(5 CYCLOPROPYL 1H PYRAZOL 3 YL)AMINO]PYRROLO[2,1 F][1,2,4]TRIAZIN 2 YL] N (6 FLUORO 3 PYRIDINYL) 2 METHYL 2 PYRROLIDINECARBOXAMIDE; MONOCLONAL ANTIBODY; PYRAZOLE DERIVATIVE; TRIAZINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL ACTIVATION; CELL PROLIFERATION; DOWN REGULATION; DRUG ACTIVITY; DRUG MECHANISM; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHABDOMYOSARCOMA; SIGNAL TRANSDUCTION; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; DEFICIENCY; DRUG RESISTANCE; DRUG SCREENING; GENE DOSAGE; GENE EXPRESSION REGULATION; GENE SILENCING; GENETIC TRANSFECTION; GENETICS; IMMUNOLOGY; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; GENE DOSAGE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; MICE; PYRAZOLES; RECEPTOR, IGF TYPE 1; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; RHABDOMYOSARCOMA; TRANSFECTION; TRIAZINES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77956922669     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-0391     Document Type: Article

References (29)

1. Samani AA, Yakar S, LeRoith D, et al. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev 2007;28:20-47.
2. Morrione A, Valentinis B, Xu SQ, et al. Insulin-like growth factor II stimulates cell proliferation through the insulin receptor. Proc Natl Acad Sci U S A 1997;94:3777-82.
3. Denley A, Cosgrove LJ, Booker GW, Wallace JC, Forbes BE. Molecular interactions of the IGF system. Cytokine Growth Factor Rev 2005;16:421-39.
4. Pandini G, Vigneri R, Costantino A, et al. Insulin and insulin-like growth factor-I (IGFI) receptor overexpression in breast cancers leads to insulin/IGF-I hybrid receptor overexpression: evidence for a second mechanism of IGF-I signaling. Clin Cancer Res 1999;5:1935-44.
5. Hendrickson AW, Haluska P. Resistance pathways relevant to insulin-like growth factor-1 receptor-targeted therapy. Curr Opin Investig Drugs 2009;10:1032-40.
6. Law JH, Habibi G, Hu K, et al. Phosphorylated insulin-like growth factor-I/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res 2008;68:10238-46.
7. Gualberto A, Pollak M. Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions. Oncogene 2009;28:3009-21.
8. Rodon J, DeSantos V, Ferry RJ, Kurzrock R. Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: lessons from the first clinical trials. Mol Cancer Ther 2008;7:2575-88.
9. Weroha SJ, Haluska P. IGF-I receptor inhibitors in clinical trials - early lessons. J Mamm Gland Biol Neoplasia 2008;13:471-83.
10. Carboni JM, Wittman M, Yang Z, et al. BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR. Mol Cancer Ther 2009;8:3341-9.
11. Clemens PL, Park JS, Cohen MB, et al. BMS-754807, an oral dual IGF-IR/IR inhibitor: first-in-human single-dose study of safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy subjects. Proceedings of the AACR-NCI-EORTC International Conference; 2009 November 15-19, Boston, MA. abstract #101.
12. Desai J, Solomon B, Davis ID, et al. BMS-754807, an oral dual IGF-IR/Insulin receptor (IR) inhibitor: early pharmacodynamic (PD) and positron emission tomography (PET) imaging results from a dailydose study in cancer subjects. Proceedings of the AACR-NCI-EORTC International Conference; 2009 November 15-19, Boston (MA). abstract #109.
13. Jänne PA, Gray N, Settleman J. Factors underlying sensitivity of cancers to kinase inhibitors. Nat Rev Drug Discov 2009;8:709-23.
14. Engelman JA, Settleman J. Acquired resistance to tyrosine kinase inhibitors during cancer therapy. Curr Opin Genet Dev 2008;18:73-9.
15. Hailey J, Maxwell E, Koukouras K, Bishop WR, Pachter JA, Wang Y. Neutralizing anti-insulin-like growth factor receptor 1 antibodies inhibit receptor function and induce receptor degradation in tumor cells. Mol Cancer Ther 2002;1:1349-53.
16. Huang F, Greer A, Hurlburt W, et al. The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors. Cancer Res 2009;69:161-70.
17. Bengtsson H, Wirapati P, Speed TP. A single-array preprocessing method for estimating full-resolution raw copy numbers from all Affymetrix genotyping arrays including GenomeWideSNP 5 & 6. Bioinformatics 2009;25:2149-56.
18. Olshen AB, Venkatraman ES, Lucito R, Wigler M. Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics 2004;5:557-72.
19. Homsi J, Daud AI. Spectrum of activity and mechanism of action of VEGF/PDGF inhibitors. Cancer Control 2007;14:285-94.
20. Zha J, O'Brien C, Savage H, et al. Molecular predictors of response to a humanized anti-insulin-like growth factor-I receptor monoclonal antibody in breast and colorectal cancer. Mol Cancer Ther 2009;8:2110-21.
21. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316:1039-43.
22. McDermott U, Pusapati RV, Christensen JG, Gray NS, Settleman J. Acquired resistance of non-small cell lung cancer cells to MET kinase inhibition is mediated by a switch to epidermal growth factor receptor dependency. Cancer Res 2010;70:1625-34.
23. Fleming TP, Saxena A, Clark WC, et al. Amplification and/or overexpression of platelet-derived growth factor receptors and epidermal growth factor receptor in human glial tumors. Cancer Res 1992;52:4550-3.
24. Zhao J, Roth J, Bode-Lesniewska B, Pfaltz M, Heitz PU, Komminoth P. Combined comparative genomic hybridization and genomic microarray for detection of gene amplifications in pulmonary artery intimal sarcomas and adrenocortical tumors. Genes Chromosomes Cancer 2002;34:48-57.
25. Mahadevan D, Cooke L, Riley C, et al. A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal tumors. Oncogene 2007;26:3909-19.
26. Liu L, Greger J, Shi H, et al. Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL. Cancer Res 2009;69:6871-8.
27. Hong CC, Lay JD, Huang JS, et al. Receptor tyrosine kinase AXL is induced by chemotherapy drugs and overexpression of AXL confers drug resistance in acute myeloid leukemia. Cancer Lett 2008;268:314-24.
28. Mendelsohn J, Baselga J. Epidermal growth factor receptor targeting in cancer. Semin Oncol 2006;33:369-85.
29. Imai K, Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer 2006;6:714-27.